分组1 - Richardson Electronics, Ltd. reported better-than-expected first-quarter financial results, with earnings of 13 cents per share, surpassing the analyst consensus estimate of 1 cent per share [1] - The company achieved quarterly sales of $54.607 million, exceeding the analyst consensus estimate of $51.510 million [1] - Following the positive earnings report, Richardson Electronics shares increased by 20.2% to $12.76 in pre-market trading [1] 分组2 - Turn Therapeutics Inc. saw a significant gain of 226.3%, reaching $22.84 in pre-market trading after commencing trading on the Nasdaq Capital Market [5] - Baosheng Media Group Holdings Limited surged by 107.7% to $6.88 in pre-market trading [5] - Several other companies also experienced notable pre-market trading gains, including Alaunos Therapeutics, Inc. (+61.5%), Ambow Education Holding Ltd. (+53.2%), and AiRWA Inc. (+45.7%) [5]

Core Findings - Telomir Pharmaceuticals, Inc. announced new preclinical results indicating that its investigational therapy Telomir-1 can restore the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of key genes MASPIN and RASSF1A in aggressive prostate cancer models [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies that target epigenetic drivers of cancer, aging, and age-related diseases [1] Group 2: Research Findings - Telomir-1 reactivates two critical tumor suppressor genes, MASPIN and RASSF1A, which are essential for blocking invasion, limiting metastasis, and improving chemotherapy responsiveness in prostate cancer [1]

Market Overview - U.S. stock futures declined on Tuesday following mixed movements on Monday, with major benchmark indices showing lower futures [1] - The Advanced Micro Devices Inc. (NASDAQ:AMD) deal with OpenAI contributed to a rally in AI-linked stocks, which has been a driving force behind Wall Street's bull run this year [1] Economic Indicators - The U.S. government shutdown, now in its seventh day, has delayed the release of the U.S. trade deficit data [2] - The 10-year Treasury bond yield is at 4.17%, while the two-year bond yield stands at 3.59% [2] - Market expectations indicate a 92.5% likelihood of the Federal Reserve cutting interest rates in its upcoming October meeting [2] Futures Performance - Dow Jones futures decreased by 0.18%, S&P 500 by 0.08%, Nasdaq 100 by 0.04%, and Russell 2000 by 0.13% [3] - The SPDR S&P 500 ETF Trust (NYSE:SPY) fell by 0.037% to $671.36, while Invesco QQQ Trust ETF (NASDAQ:QQQ) rose by 0.0099% to $607.77 in premarket trading [3] Stocks in Focus - Trilogy Metals Inc. (NYSE:TMQ) surged by 180.38% in premarket trading after the White House announced a $35.6 million investment for a 10% stake to support mining exploration in Alaska's Ambler Mining District [8] - Advanced Micro Devices Inc. (NASDAQ:AMD) increased by 2.57% following a deal with OpenAI to supply Instinct GPU accelerators for AI infrastructure [9] - Applovin Corp. (NASDAQ:APP) fell by 2.56% amid an SEC investigation into its data-collection practices [10] - Telomir Pharmaceuticals Inc. (NASDAQ:TELO) jumped by 30.99% after releasing promising preclinical study results for its lead compound [11] Analyst Insights - Corporate America is expected to deliver a strong earnings season for Q3 2025, with a forecasted low-teens earnings growth rate for the S&P 500 [16] - Factors contributing to this outlook include a resilient economy, strong AI investment, and a weaker U.S. dollar [17] - Analysts predict a 5% earnings beat above current consensus estimates for the third quarter, despite potential tariff pressures [18]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

Earnings Expectations - Wall Street anticipates McCormick & Company Inc. to report quarterly earnings of 81 cents per share with revenue projected at $1.71 billion [2] - Analysts expect Penguin Solutions Inc. to post quarterly earnings of 38 cents per share on revenue of $342.11 million [2] - Saratoga Investment Corp. is expected to report quarterly earnings of 68 cents per share with revenue of $31.98 million [2] Stock Performance - McCormick shares increased by 1.3% to $69.19 in after-hours trading [2] - SANUWAVE Health Inc. shares fell by 19.2% to $33.00 after issuing preliminary third-quarter revenue results below estimates and cutting FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [2] - Penguin Solutions shares rose by 1.7% to $29.80 in after-hours trading [2] - Telomir Pharmaceuticals Inc. shares surged by 38.7% to $1.97 following promising preclinical study results for its lead compound, Telomir-1 [2]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Core Viewpoint - Telomir Pharmaceuticals Inc. experienced a significant stock price increase of 38.71% in after-hours trading following the announcement of promising preclinical study results for its lead compound, Telomir-1, which is aimed at reversing DNA methylation in aggressive prostate cancer models [1][2]. Group 1: Study Results - Telomir-1 was reported to reverse abnormal DNA methylation, restoring the function of key tumor suppressor genes MASPIN and RASSF1A, which are often silenced in cancer due to hypermethylation [2][3]. - MASPIN is critical for blocking tumor invasion, regulating cell migration, promoting apoptosis, and enhancing treatment sensitivity. Telomir-1 effectively restored MASPIN activity in vivo by reversing chemotherapy-induced DNA methylation [4]. - RASSF1A is involved in cell cycle control, promoting apoptosis, and suppressing metastasis. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with enhanced effects when combined with chemotherapy [5]. Group 2: Development Status - The company is continuing preclinical development with IND-enabling studies for Telomir-1 [6]. Group 3: Stock Performance - Year-to-date, TELO stock is down 65.53%, but has gained 15.45% over the past month. The stock has traded between $1.12 and $7.08 over the past year, with a market capitalization of $45.84 million and an average daily trading volume of 3.33 million shares [7].

Core Insights - Telomir Pharmaceuticals, Inc. has announced new in vitro results indicating that Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, suggesting a potential advancement in epigenetic therapy [1] Company Summary - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing therapies that target the root causes of cancer, aging, and age-related diseases [1] - The company is listed on NASDAQ under the ticker TELO [1] Industry Summary - The results from Telomir-1 may represent a novel frontier in epigenetic therapy, an area where no existing candidates have demonstrated comparable breadth [1] - The inhibition of three members of the KDM5 histone demethylase family by Telomir-1 highlights the potential for innovative therapeutic approaches in the field of epigenetics [1]

Financial Performance - For the three months ended June 30, 2025, the company reported a net loss of $5.1 million, compared to a net loss of $1.4 million for the same period in 2024, representing a significant increase in losses [78]. - The company incurred a total net loss of $7.2 million for the six months ended June 30, 2025, compared to a net loss of $7.7 million for the same period in 2024 [78]. - The company reported negative cash flow from operations of approximately $1.6 million for the six months ended June 30, 2025, compared to $3.5 million for the same period in 2024 [101]. Expenses - Research and development expenses for the three months ended June 30, 2025, were $0.04 million, a decrease from $0.6 million in the same period of 2024, primarily due to a credit received in 2024 [89]. - General and administrative expenses increased to $5.0 million for the three months ended June 30, 2025, from $0.9 million in 2024, largely due to a $4.6 million increase in stock compensation expenses [94]. - The company expects research and development expenses to increase as it advances Telomir-1 into clinical trials and pursues regulatory approvals [93]. Cash Position - As of June 30, 2025, the company had cash and cash equivalents of approximately $0.8 million and an accumulated deficit of approximately $37.8 million [101]. - The company has entered into an unsecured Promissory Note with the Starwood Trust, allowing it to borrow up to $5 million, with no amounts borrowed as of June 30, 2025 [99]. Funding - The company raised $3 million in equity financing through a direct investment by The Bayshore Trust, issuing 333,333 restricted shares at $3.00 per share, an 18% premium to the closing share price on the execution date [100]. Revenue Generation - The company has not generated any revenue since inception and does not anticipate doing so until successful completion of preclinical and clinical development [91].

Company Performance - 3M Company reported second-quarter 2025 results with GAAP sales of $6.3 billion, reflecting a year-over-year increase of 1.4% and adjusted sales of $6.2 billion, which beat the consensus estimate of $6.09 billion [2] - Adjusted earnings per share rose 12% year over year to $2.16, surpassing the Street estimate of $2.01 [2] Future Guidance - 3M raised its 2025 Adjusted EPS guidance to a range of $7.75-$8.00 from a prior range of $7.60-$7.90, compared to the consensus of $7.68 [3] - The company expects 2025 adjusted sales organic growth of approximately 2%, with operating cash flow projected between $5.1 billion and $5.5 billion, indicating over 100% free cash flow conversion [3] Stock Movements - Telomir Pharmaceuticals, Inc. saw its shares increase by 81% to $2.19 following the announcement of gene silencing data [8] - MEI Pharma, Inc. shares surged 33% to $5.99 after announcing a $100 million private placement [8] - Blaize Holdings, Inc. shares rose 45% to $4.39 after a $120 million agreement for deploying its hybrid AI platform [8] - LQR House Inc. shares dropped 65% to $2.29 due to plans to integrate cryptocurrency and blockchain technology [8] - Northern Dynasty Minerals Ltd. shares fell 48% to $0.8398 after insider trading disclosures [8] - Draganfly Inc. shares decreased by 23% to $5.55 following a $25 million registered direct offering [8]